How do I safely discontinue Quetiapine (Seroquel)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Safely Discontinue Quetiapine (Seroquel)

Quetiapine should be tapered gradually over a period of weeks to months, with dose reductions of approximately 25% every 1-2 weeks to minimize withdrawal symptoms and prevent relapse. 1, 2

Understanding Quetiapine Discontinuation Risks

  • Abrupt discontinuation of quetiapine can lead to withdrawal symptoms including insomnia, nausea, vomiting, headache, dizziness, irritability, and anxiety 1
  • Sudden cessation is considered unacceptable medical care and may lead to increased risk of relapse 3
  • Withdrawal symptoms may be mistaken for recurrence of the original condition, potentially leading to unnecessary long-term medication continuation 4
  • Discontinuation symptoms typically emerge after abrupt discontinuation or intermittent non-compliance 5

Recommended Tapering Protocol

Initial Steps

  • Begin with a 25% reduction of the current dose and maintain for 1-2 weeks 3, 2
  • Monitor for withdrawal symptoms such as insomnia, nausea, anxiety, and irritability during this period 1
  • If significant withdrawal symptoms occur, slow the taper or temporarily return to the previous dose 3

Continuing the Taper

  • After successful adaptation to the first reduction, continue with sequential reductions of 25% of the most recent dose every 1-2 weeks 2
  • As the dose decreases, the absolute size of each reduction becomes smaller (hyperbolic tapering) 2
  • For patients on higher doses, consider longer intervals between reductions (3-4 weeks) 2
  • Final doses before complete cessation may need to be very small (as low as 1/40th of the therapeutic dose) 2

Special Considerations

  • Patients with a history of relapse may benefit from a more gradual taper over months rather than weeks 2
  • If taking quetiapine with other CNS depressants like clonazepam, consider tapering quetiapine first before addressing the benzodiazepine 6
  • For elderly patients or those with medical comorbidities, use even more gradual tapering schedules 1

Managing Withdrawal Symptoms

  • Common withdrawal symptoms include sleep disturbances, nausea, headache, dizziness, irritability, and anxiety 1, 5
  • For mild symptoms, reassurance about their transient nature may be sufficient 5
  • For more severe symptoms:
    • Temporarily pause the taper or return to the previous dose 3
    • Consider adjunctive medications for specific symptoms (e.g., antihistamines for sleep, anti-nausea medications) 3
    • Resume tapering at a slower rate once symptoms subside 3

Monitoring During Discontinuation

  • Regular assessment for withdrawal symptoms at each dose reduction 1
  • Distinguish between withdrawal symptoms and recurrence of the original condition 4
  • Monitor for changes in sleep, mood, anxiety, and physical symptoms 5
  • Be alert for signs of relapse of the original condition requiring treatment 1

Common Pitfalls to Avoid

  • Tapering too quickly (less than 2 weeks) offers minimal benefits over abrupt discontinuation 4
  • Mistaking withdrawal symptoms for relapse of the original condition 4
  • Failing to prepare patients for possible withdrawal effects 3
  • Not providing adequate support during the tapering process 3
  • Stopping at minimum therapeutic doses rather than continuing to lower doses 4, 2

Long-term Follow-up

  • Schedule follow-up appointments throughout the tapering process 3
  • Continue monitoring for several weeks after complete discontinuation as some withdrawal effects can be delayed 1
  • Have a contingency plan if symptoms worsen or relapse occurs 3
  • Consider psychological support strategies during the tapering process 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical management of antidepressant discontinuation.

The Journal of clinical psychiatry, 1997

Guideline

Concurrent Use of Quetiapine and Clonazepam: Safety Considerations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.